Beijing Immunochina Medical Science and Technology

Beijing Immunochina Medical Science and Technology (also known as Yimiao Shenzhou) is a clinical-stage biopharmaceutical firm established in 2015. The company was founded by three PhD graduates from Tsinghua University's School of Life Sciences: He Ting, Lu Xinan, and Qi Feifei. Their academic background in life sciences provided the foundation for the company's focus on developing advanced medical treatments. He Ting serves as the company's CEO.

The firm concentrates on the research and development of gene and cell therapies to address serious illnesses like cancer and autoimmune disorders. Its primary business revolves around Chimeric Antigen Receptor T-cell (CAR-T) therapy, a type of immunotherapy that modifies a patient's own T-cells to identify and attack cancer cells. The company's client base consists of patients with various forms of cancer, and it operates within the innovative biopharmaceutical market, which is characterized by extensive research and clinical trials. Revenue generation is anticipated through the commercialization of its approved drug candidates.

Immunochina has developed a comprehensive platform for gene and cell therapy, covering all essential aspects from research to industrialization. The company's product pipeline includes treatments for hematologic cancers such as lymphoma, leukemia, and multiple myeloma, as well as solid tumors like liver and colorectal cancer. One of its key product candidates is IM19, an independently developed CAR-T cell therapy targeting CD19 for treating relapsed or refractory B-cell non-Hodgkin lymphoma. The company has received multiple Investigational New Drug (IND) approvals in China and is advancing its products through clinical trials. For instance, the IM19 product has shown a 68% continuous remission rate at 12 months in clinical studies. Another notable product, IM96, targets metastatic colorectal cancer and has demonstrated promising results in early clinical trials by addressing challenges related to T-cell infiltration into solid tumors.

Since its inception, Immunochina has secured significant funding through multiple investment rounds, enabling its research and development activities. By January 2025, the company had completed ten rounds of strategic financing. The company has also initiated the process for an IPO on the STAR Market of the Shanghai Stock Exchange, indicating its plans for future growth and commercial expansion.

Keywords: CAR-T cell therapy, gene therapy, immunotherapy, oncology, biopharmaceutical, clinical trials, hematologic malignancies, solid tumors, B-cell lymphoma, leukemia, colorectal cancer, autoimmune disorders, cell and gene therapies, drug development, clinical-stage, life sciences, cancer treatment, IM19, IM96, Yimiao Shenzhou